Mechanisms of sarcoma development

Nature Reviews Cancer

Volumn 3, Issue 9, 2003, Pages 685-694

  Helman, Lee J ^a   Meltzer, Paul ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED KINASE RECEPTOR; GROWTH FACTOR; PROTEIN P53; PROTEIN TYROSINE KINASE; RETINOBLASTOMA PROTEIN; TYROSINE KINASE GROWTH FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; BONE; CANCER CLASSIFICATION; CANCER SUSCEPTIBILITY; CARTILAGE; CHROMOSOMAL INSTABILITY; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CONNECTIVE TISSUE; GENE MUTATION; GENETIC DISORDER; GENETIC MODEL; GENETIC PREDISPOSITION; KARYOTYPE; MUSCLE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SARCOMA; SIGNAL TRANSDUCTION; ANIMAL; CONNECTIVE TISSUE TUMOR; DNA MICROARRAY; GENE TRANSLOCATION; GENETICS; HUMAN; METHODOLOGY;

ANIMALS; HUMANS; MODELS, ANIMAL; NEOPLASMS, CONNECTIVE TISSUE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SARCOMA; SIGNAL TRANSDUCTION; TRANSLOCATION, GENETIC;

EID: 0141799898     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1168     Document Type: Review

References (93)

1. US Cancer Statistics Working Group, Department of Health and Human Services United States Cancer Statistics: 1999 Incidence (Centers for Disease Control and Prevention and National Cancer Institute, Atlanta, 2002).
2. Jemal, A. et al. Cancer statistics, 2003. CA Cancer J. Clin. 53, 5-26 (2003).
3. Abramson, D. H., Ellsworth, R. M., Kitchin, F. D. & Tung, G. Second nonocular tumors in retinoblastoma survivors. Are they radiation-induced? Ophthalmology 91, 1351-1355 (1984).
4. Wong, F. L. et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 278, 1262-1267 (1997).
5. Li, F. P. & Fraumeni, J. F. Jr. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J. Natl Cancer Inst. 43, 1365-1373 (1969).
6. Malkin, D. et al. Germ line p53 mutations in a familial syndrome of breast cancer sarcomas, and other neoplasms. Science 250, 1233-1238 (1990). First identification of germline mutations of TP53 in families with Li-Fraumeni syndrome.
7. King, A. A., Debaun, M. R., Riccardi, V. M. & Gutmann, D. H. Malignant peripheral nerve sheath tumors in neurofibromatosis 1. J. Am. J. Med. Genet. 93, 388-392 (2000).
8. Nishida, T. et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nature Genet. 19, 323-324 (1998).
9. Evans, D. M., Williams, W. J. & Kung, I. T. Angiosarcoma and hepatocellular carcinoma in vinyl chloride workers. Histopathology 7, 377-388 (1983).
10. Elliott, P. & Kleinschmidt, I. Angiosarcoma of the liver in Great Britain in proximity to vinyl chloride sites. Occup. Environ. Med. 54, 14-18 (1997).
11. Mark, R. J. et al. Postirradiation sarcomas. A single-institution study and review of the literature. Cancer 73, 2653-2662 (1994).
12. Sandberg, A. A. & Bridge, J. A. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: mesothelloma. Cancer Genet. Cytogenet. 127, 93-110 (2001).
13. Sandberg, A. A. & Bridge, J. A. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: desmoplastic small round-cell tumors. Cancer Genet. Cytogenet. 138, 1-10 (2002).
14. Sandberg, A. & Bridge, J. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: alveolar soft part sarcoma. Cancer Genet. Cytogenet. 138, 1-9 (2002).
15. Sandberg, A. A. & Bridge, J. A Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: gastrointestinal stromal tumors. Cancer Genet. Cytogenet. 135, 1-22 (2002).
16. Sandberg, A. A. & Bridge, J. A. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: synovial sarcoma. Cancer Genet. Cytogenet. 133, 1-23 (2002).
17. Sandberg, A. A. & Bridge, J. A. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: congenital (infantile) fibrosarcoma and mesoblastic nephroma. Cancer Genet. Cytogenet. 132, 1-13 (2002).
18. Sandberg, A. A. & Bridge, J. A. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: dermatofibrosarcoma protuberans and giant cell fibroblastoma. Cancer Genet. Cytogenet. 140, 1-12 (2003).
19. Fredericks, W. J. et al. The PAX3-FKHR fusion protein created by the t(2; 13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol. Cell Biol. 15, 1522-1535 (1995).
20. Bennicelli, J. L., Edwards, R. H. & Barr, F. G. Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma. Proc. Natl Acad. Sci. USA 93, 5455-5459 (1996).
21. Zhang, L. & Wang, C. PAX3-FKHR transformation increases 26 S proteasome-dependent degradation of p27Kp1, a potential role for elevated Skp2 expression. J. Biol. Chem. 278, 27-36 (2003).
22. Barber, T. D. et al. Identification of target genes regulated by PAX3 and PAX3-FKHR in embryogenesis and alveolar rhabdomyosarcoma. Genomics 79, 278-284 (2002).
23. Khan, J. et al. Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res. 56, 5009-5013 (1998). Demonstration that a specific gene-expression profile can be associated with an alveolar rhabdomyosarcoma by microarray technology.
24. de Alava, E. et al. Prognostic impact of p53 status in Ewing sarcoma. Cancer 89, 783-792 (2000).
25. Wei, G. et al. Prognostic impact of INK4A deletion in Ewing sarcoma. Cancer 89, 793-799 (2000).
26. de Alava, E. et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J. Clin. Oncol. 16, 1248-1255 (1998).
27. Ladanyi, M. et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res. 62, 135-140 (2002).
28. Sorensen, P. H. et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J. Clin. Oncol. 20, 2672-2679 (2002).
29. Lin, P. P. et al. Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma. Cancer Res. 59, 1428-1432 (1999).
30. Stratton, M. R. et al. Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene. Oncogene 5, 1297-1301 (1990).
31. Del Tos, A. P. et al. Tumor suppressor genes and related molecules in leiomyosarcoma. Am. J. Pathol. 148, 1037-1045 (1996).
32. Nakanishi, H. et al. Mutation of the p53 gene in postradiation sarcoma. Lab. Invest. 78, 727-733 (1998).
33. Donehower, L. A. et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221 (1992).
34. Harvey, M. et al. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nature Genet. 5, 225-229 (1993).
35. Kamijo, T., Bodner, S., van de Kamp, E., Randle, D. H. & Sherr, C. J. Tumor spectrum in ARF-deficient mice. Cancer Res. 59, 2217-2222 (1999).
36. Sharpless, N. E. et al. Impaired nonhomologous end-joining provokes soft tissue sarcomas harboring chromosomal translocations, amplifications, and deletions. Mol. Cell 8, 1187-1196 (2001). Demonstration that mice that are prone to chromosomal abnormalities due to a defect in DNA repair become prone to the development of sarcomas.
37. Gisselsson, D. et al. A case of dermatofibrosarcoma protuberans with a ring chromosome 5 and a rearranged chromosome 22 containing amplified COL1A1 and PDGFB sequences. Cancer Lett. 133, 129-134 (1998).
38. Simon, M. P. et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nature Genet. 15, 95-98 (1997). Demonstration of activation of PDGFB in dermatofibrosarcoma protuberans through a translocation and fusion with the COL1A1 gene.
39. O'Brien, K. P. et al. Various regions within the alpha-helical domain of the COL1A1 gene are fused to the second exon of the PDGFB gene in dermatofibrosarcomas and giant-cell fibroblastomas. Genes Chromosom. Cancer 23, 187-193 (1998).
40. Shimizu, A. et al. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res. 59, 3719-3723 (1999).
41. Rubin, B. P. et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J. Clin. Oncol. 20, 3586-3591 (2002).
42. Meza-Zepeda, L. A. et al. Positional cloning identifies a novel cyclophilin as a candidate amplified oncogene in 1q21. Oncogene 21, 2261-2269 (2002).
43. Pinkel, D. et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nature Genet. 20, 207-211 (1998). By using genomic clones in a microarray format, it was possible to obtain superior resolution in comparative genomic hybridization.
44. Fritz, B. et al. Microarray-based copy number and expression profiling in dedifferentiated and pleomorphic liposarcoma. Cancer Res. 62, 2993-2998 (2002).
45. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell 81, 323-330 (1995).
46. Cohen, J. A. & Geradts, J. Loss of RB and MTS1/CDKN2 (p16) expression in human sarcomas. Hum. Pathol. 28, 893-898 (1997).
47. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell 88, 323-331 (1997).
48. Giaccia, A. J. & Kastan, M. B. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 12, 2973-2983 (1998).
49. Creager, A. J., Cohen, J. A. & Geradts, J. Aberrant expression of cell-cycle regulatory proteins in human mesenchymal neoplasia. Cancer Detect. Prev. 26, 123-131 (2001).
50. Leach, F. S. et al. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 53, 2231-2234 (1993).
51. Hoppener, J. W. et al. Expression of insulin-like growth factor-I and-II genes in human smooth muscle tumours. EMBO J. 7, 1379-1385 (1988).
52. Roholl, P. J. et al. Expression of insulin-like growth factor 1 in sarcomas. Histopathology 16, 455-460 (1990).
53. Deitel, K. et al. Reduced growth of human sarcoma xenografts in hosts homozygous for the lit mutation. J. Surg. Oncol. 81, 75-79 (2002).
54. Kalebic, T. et al. Expression of a kinase-deficient IGF-I-R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing a wild type IGF-I-R. Int. J. Cancer 76, 223-227 (1998).
55. McGary, E. C. et al. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin. Cancer Res. 8, 3584-3591 (2002).
56. Lee, S. B. et al. The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour. Nature Genet. 17, 309-313 (1997).
57. Merchant, M. S., Woo, C. W., Mackall, C. L. & Thiele, C. J. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity. J. Natl Cancer Inst. 94, 1673-1679 (2002).
58. Hornick, J. L. & Fletcher, C. D. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am. J. Clin. Pathol. 117, 158-193 (2002).
59. Berman, J. & O'Leary, T. J. Gastrointestinal stromal tumor workshop. Hum. Pathol. 32, 578-582 (2001).
60. Rubin, B. P. et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 61, 8118-8121 (2001). Shows activation of KIT in the majority of GISTs.
61. Wallenius, V. et al. Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors. Am. J. Pathol. 156, 821-829 (2000).
62. Tamborini, E. et al. c-KIT and c-KIT ligand (SCF) in synovial sarcoma (SS): an mRNA expression analysis in 23 cases. Br. J. Cancer 85, 405-411 (2001).
63. Oda, Y. et al. Expression of hepatocyte growth factor (HGF)/scatter factor and its receptor c-MET correlates with poor prognosis in synovial sarcoma. Hum. Pathol. 31, 185-192 (2000).
64. Ferracini, R. et al. Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas. Oncogene 12, 1697-1705 (1996).
65. El-Badry, O. M. et al. Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ. 1, 325-331 (1990).
66. Minniti, C. P., Tsokos, M., Newton, W. A. Jr. & Helman, L. J. Specific expression of insulin-like growth factor-II in rhabdomyosarcoma tumor cells. Am. J. Clin. Pathol. 101, 198-203 (1994).
67. Greaves, M., Maia, A. T., Wiemels, J. L. & Ford, A. M. Leukemia in twins: lessons in natural history. Blood (in the press).
68. Wang, W. et al. Insulin-like growth factor II and PAX3-FKHR cooperate in the oncogenesis of rhabdomyosarcoma. Cancer Res. 56, 4426-4433 (1998).
69. Knezevich, S. R. et al. ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. Cancer Res. 56, 5046-5048 (1998). Identification of the identical genetic alteration of mesoblastic nephroma and congenital fibrosarcoma, linking these two tumours as genetically identical.
70. Allander, S. V. et al. Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile. Cancer Res. 61, 8624-8648 (2001).
71. Allander, S. V. et al. Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am. J. Pathol. 161, 1587-1595 (2002).
72. Khan, J. et al. cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc. Natl Acad. Sci. USA 96, 13264-13269 (1999).
73. Nagayama, S. et al. Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res. 62, 5859-5866 (2002).
74. Sjogren, H. et al. Studies on the molecular pathogenesis of extraskeletal myxoid chondrosarcoma-cytogenetic, molecular genetic, and cDNA microarray analyses. Am. J. Pathol. 162, 781-792 (2003).
75. Nielsen, T. O. et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 359, 1301-1307 (2002).
76. Lessnick, S. L., Dacwag, C. S. & Golub, T. R. The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell 1, 393-401 (2002).
77. Deneen, B. et al. PIM3 proto-oncogene kinase is a common transcriptional target of divergent EWS/ETS oncoproteins. Mol. Cell. Biol. 23, 3897-3908 (2003).
78. Barone, M. V., Crozat, A., Tabaee, A., Philipson, L. & Ron, D. CHOP (GADD153) and its oncogenic variant, TLS-CHOP, have opposing effects on the induction of G1/S arrest. Genes Dev. 8, 453-464 (1994).
79. Adelmant, G., Gilbert, J. D. & Freytag, S. O. Human translocation liposarcoma-CCAAT/enhancer binding protein (C/EBP) homologous protein (TLS-CHOP) oncoprotein prevents adipocyte differentiation by directly interfering with C/EBPbeta function. J. Biol. Chem. 273, 15574-15581 (1998).
80. Rapp, T. B., Yang, L., Conrad, E. U., Mandahl, N. & Chansky, H. A. RNA splicing mediated by YB-1 is inhibited by TLS/CHOP in human myxoid liposarcoma cells. J. Orthop. Res. 20, 723-729 (2002).
81. Knoop, L. L. & Baker, S. J. EWS/FLI alters 5′-splice site selection. J. Biol. Chem. 276, 22317-22322 (2001).
82. Knoop, L. L. & Baker, S. J. The splicing factor U1C represses EWS/FLI-mediated transactivation. J. Biol. Chem. 275, 24865-24871 (2000).
83. Perez-Losada, J. et al. Liposarcoma initiated by FUS/TLS-CHOP: the FUS/TLS domain plays a critical role in the pathogenesis of liposarcoma. Oncogene 19, 6015-6022 (2000).
84. Perez-Mancera, P. A. et al. Expression of the FUS domain restores liposarcoma development in CHOP transgenic mice. Oncogene 21, 1679-1684 (2002).
85. Lagutina, I., Conway, S. J., Sublett, J. & Grosveld, G. C. Pax3-FKHR knock-in mice show developmental aberrations but do not develop tumors. Mol. Cell. Biol. 22, 7204-7216 (2002).
86. Scrable, H. et al. A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting. Proc. Natl Acad. Sci. USA 86, 7480-7484 (1989).
87. Hahn, H. et al. Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J. Biol. Chem. 275, 28341-28344 (2000).
88. Merlino, G. & Helman, L. J. Rhabdomyosarcoma - working out the pathways. Oncogene 18, 5340-5348 (1999).
89. Sharp, R. et al. Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nature Med. 8, 1276-1280 (2002). Construction of a genetic model of rhabdomyosarcoma with nearly complete penetrance.
90. van Oosterom, A. T. et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358, 1421-1423 (2001). First large clinical trial showing the remarkable effectiveness of imatinib in GISTs.
91. Heinrich, M. C. et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299, 708-710 (2003).
92. Dancey, J. & Sausville, E. A. Issues and progress with protein kinase inhibitors for cancer treatment. Nature Rev. Drug Discov. 2, 296-313 (2003).
93. Druker, B. J. & Lydon, N. B. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest. 105, 3-7 (2000).